Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus (challenge)
Primary Purpose
Barrett's Esophagus
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sedated Endoscopy
Transnasal Endoscopy
Sponsored by
About this trial
This is an interventional screening trial for Barrett's Esophagus focused on measuring Barrett's Esophagus
Eligibility Criteria
Inclusion Criteria:
- Olmsted county, Minnesota resident
- Age 50 or older
- Able to give informed consent
Exclusion Criteria:
- History of known Barretts Esophagus (BE) or endoscopy within the last 10 years
- History of progressive dysphagia
- Known Zenkers or epiphrenic diverticulum
- History of recurrent epistaxis
- Illnesses that impair ability to complete questionnaires (e.g. metastatic cancer, stroke, dementia)
- Contraindication to esophageal biopsy (such as anticoagulation using warfarin or clopidogrel).
Sites / Locations
- Mayo Clinic in Rochester
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Sedated Endoscopy
Transnasal Endoscopy at Hospital Unit
Transnasal Endoscopy at Mobile Unit
Arm Description
Sedated esophagogastroduodenoscopy with biopsy
Unsedated transnasal endoscopy at hospital unit.
Unsedated transnasal endoscopy in mobile research van
Outcomes
Primary Outcome Measures
Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment
This outcome measure was defined as the proportion of subjects who agreed to undergo esophageal assessment in the three groups out of those who were eligible to be contacted for participation in screening.
Secondary Outcome Measures
Rate of Successful Intubation
The rate of successful intubation was defined as the ability to traverse the upper esophageal sphincter and visualize the esophageal mucosa and classified as successful or unsuccessful.
Rate of Complete Evaluation
The rate of complete evaluation was defined as visualization of the whole esophagus and identification of landmarks: squamocolumnar junction, gastroesophageal junction (upper margin of gastric folds with stomach deflated), and the diaphragmatic hiatus. The categories of evaluation were classified as complete (all three landmarks identified), incomplete (some landmarks identified), or unsuccessful.
Rate of Acquisition of Biopsies From the Esophagus
Mean Duration of Procedure
Duration of the procedure was defined as time from the beginning of the procedure (initiation of sedation or local anesthesia) to extubation.
Mean Time From Extubation to Discharge
This outcome measures the recovery time after the procedure.
Mean Tolerability Scores
Validated pain scales (where 0 is none and 10 is severe) were used to assess the degree of pain, choking, gagging, and anxiety experienced during the procedure. Overall tolerance was rated on a scale from 0 to 10, where 0 is good, and 10 is poor tolerance.
Acceptability
Acceptability was defined as the proportion of subjects willing to undergo the procedure again in the future.
Full Information
NCT ID
NCT01288612
First Posted
January 28, 2011
Last Updated
December 23, 2014
Sponsor
Mayo Clinic
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Advancing Translational Sciences (NCATS), American College of Gastroenterology
1. Study Identification
Unique Protocol Identification Number
NCT01288612
Brief Title
Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus
Acronym
challenge
Official Title
Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
October 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Advancing Translational Sciences (NCATS), American College of Gastroenterology
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The hypothesis of this study was that the comparative effectiveness of unsedated transnasal endoscopy (uTNE) will be greater than sedated endoscopy (sEGD) in population screening for BE.
Detailed Description
Barrett's esophagus (BE), a well-known complication of Gastroesophageal Reflux (GER), is the strongest known precursor of esophageal adenocarcinoma. Thus, identifying effective screening approaches for the early detection of BE are highly desired. Current impediments to BE screening include 1) the inability to utilize sedated endoscopy (sEGD) effectively in populations and 2) current GER-based paradigms for detecting BE. Referral center studies demonstrate comparable accuracy between unsedated transnasal endoscopy (uTNE) and sEGD. However, patient acceptability and diagnostic yield with uTNE in general populations remain unknown.
Using the Rochester, Minnesota Epidemiology Project resources, random samples of Olmsted County residents were drawn, and those subjects were mailed validated gastrointestinal symptom questionnaires. These surveys allowed identification of a cohort of community subjects well characterized by the frequency of reflux symptoms. Eligible subjects who were greater than or equal to 50 years old, and who had no previous history of endoscopic evaluation and who were not known to have BE were randomized, stratified by age, sex, and reflux symptoms, and assigned to one of the 3 arms of the study. Subjects in each arm who met the eligibility criteria were initially sent generic invitation letters asking if they agreed to be contacted by phone in two weeks' time to inform them about a research study. If potential subjects explicitly declined to be contacted they were excluded from the study. Eligible subjects were contacted by telephone and only offered the endoscopy technique they had been randomized to. Subjects who accepted and signed an informed consent document were treated according to their randomized assignment and all 3 groups were followed up in the same manner.
Biopsies were taken from any endoscopically suspected BE and from the gastroesophageal junction and squamous mucosa in all subjects. The length of BE segment was defined using Prague criteria. All participants received a telephone call from the research coordinator 1 and 30 days after the procedure to complete validated tolerability scales and adverse events questionnaires.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Barrett's Esophagus
Keywords
Barrett's Esophagus
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
459 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sedated Endoscopy
Arm Type
Active Comparator
Arm Description
Sedated esophagogastroduodenoscopy with biopsy
Arm Title
Transnasal Endoscopy at Hospital Unit
Arm Type
Active Comparator
Arm Description
Unsedated transnasal endoscopy at hospital unit.
Arm Title
Transnasal Endoscopy at Mobile Unit
Arm Type
Active Comparator
Arm Description
Unsedated transnasal endoscopy in mobile research van
Intervention Type
Device
Intervention Name(s)
Sedated Endoscopy
Intervention Description
The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
Intervention Type
Device
Intervention Name(s)
Transnasal Endoscopy
Intervention Description
Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
Primary Outcome Measure Information:
Title
Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment
Description
This outcome measure was defined as the proportion of subjects who agreed to undergo esophageal assessment in the three groups out of those who were eligible to be contacted for participation in screening.
Time Frame
Approximately 2 weeks after invitation letter was sent
Secondary Outcome Measure Information:
Title
Rate of Successful Intubation
Description
The rate of successful intubation was defined as the ability to traverse the upper esophageal sphincter and visualize the esophageal mucosa and classified as successful or unsuccessful.
Time Frame
Visit 1
Title
Rate of Complete Evaluation
Description
The rate of complete evaluation was defined as visualization of the whole esophagus and identification of landmarks: squamocolumnar junction, gastroesophageal junction (upper margin of gastric folds with stomach deflated), and the diaphragmatic hiatus. The categories of evaluation were classified as complete (all three landmarks identified), incomplete (some landmarks identified), or unsuccessful.
Time Frame
Visit 1
Title
Rate of Acquisition of Biopsies From the Esophagus
Time Frame
Visit 1
Title
Mean Duration of Procedure
Description
Duration of the procedure was defined as time from the beginning of the procedure (initiation of sedation or local anesthesia) to extubation.
Time Frame
Visit 1
Title
Mean Time From Extubation to Discharge
Description
This outcome measures the recovery time after the procedure.
Time Frame
Visit 1
Title
Mean Tolerability Scores
Description
Validated pain scales (where 0 is none and 10 is severe) were used to assess the degree of pain, choking, gagging, and anxiety experienced during the procedure. Overall tolerance was rated on a scale from 0 to 10, where 0 is good, and 10 is poor tolerance.
Time Frame
Day 1 after the procedure
Title
Acceptability
Description
Acceptability was defined as the proportion of subjects willing to undergo the procedure again in the future.
Time Frame
Day 1 after the procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Olmsted county, Minnesota resident
Age 50 or older
Able to give informed consent
Exclusion Criteria:
History of known Barretts Esophagus (BE) or endoscopy within the last 10 years
History of progressive dysphagia
Known Zenkers or epiphrenic diverticulum
History of recurrent epistaxis
Illnesses that impair ability to complete questionnaires (e.g. metastatic cancer, stroke, dementia)
Contraindication to esophageal biopsy (such as anticoagulation using warfarin or clopidogrel).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prasad G. Iyer, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
25488897
Citation
Sami SS, Dunagan KT, Johnson ML, Schleck CD, Shah ND, Zinsmeister AR, Wongkeesong LM, Wang KK, Katzka DA, Ragunath K, Iyer PG. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett's esophagus screening in the community. Am J Gastroenterol. 2015 Jan;110(1):148-58. doi: 10.1038/ajg.2014.362. Epub 2014 Dec 9.
Results Reference
result
Learn more about this trial
Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus
We'll reach out to this number within 24 hrs